What changed for Lymphoma
A plain English summary of what recently moved in the public data Voxsanity tracks for Lymphoma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 40 to 39 (-1)
- Trials recruiting worldwide 756 to 758 (+2)
- Late-stage (Phase 3) trials 60 to 61 (+1)
- Trials on record 4,043 to 4,057 (+14)
Newly subsidised on the PBS
1 medicine newly subsidised on the PBS for Lymphoma in July 2026:
- Romidepsin
"Newly subsidised" means the medicine reached the PBS this month, not that a new pack size or brand of an existing listing was added. Verify current PBS status with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 167 trials tracked for Lymphoma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05255601 · results posted 26 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05255601) enrolled a total of 5 participants across two groups in what was called "Part A" — 4 people in a "flat dosing" group (where everyone receives the same dose) and 1 person in an "age/weight-based dosing" group (where the dose is adjusted based on the individual). Notably, none of the 5 participants completed the study, and the trial also had a planned "Part B," which never got underway because no participants enrolled in it. The primary outcome the trial was measuring in Part A was the number of participants who e...
-
NCT04257578 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04257578) enrolled 23 participants, all in the HIV-negative group. A planned HIV-positive group was included in the study design but reported zero participants started or completed the study. The trial was looking at a combination of two treatments — acalabrutinib (a tablet medicine) and axicabtagene ciloleucel (a type of personalised immune cell therapy, sometimes called CAR-T cell therapy) — in people with certain blood cancers. The main thing the trial set out to measure was how often serious side effects occurred, spec...
-
NCT02997761 · results posted 9 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 adults with a form of blood cancer called B-cell acute lymphoblastic leukaemia (a type of cancer affecting white blood cells). All 19 participants completed the study. The trial was looking at a combination of two medicines — ibrutinib and blinatumomab — and measuring things like how many participants went into remission (meaning signs of the cancer could no longer be detected in standard tests), how long participants survived, and what side effects were recorded. The reported data shows that 9 out of 19 participa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06382194 · results posted 28 April 2026
According to the results reported on ClinicalTrials.gov, this trial involved a single group of 5 participants in the intervention arm. Three participants completed the study, while two did not finish. The trial was looking at whether a decision aid (an informational tool to help people make decisions) could influence how safely firearms were stored at home, and also measured things like participants' knowledge about safe storage, how confident they felt making decisions about firearm storage, and how acceptable they found the intervention. The reported data shows that out of the 3 participant...
-
NCT06360575 · results posted 20 March 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called crizotinib in people with cancer who had a specific genetic change (mutation) in their tumour. Twenty people were enrolled, 18 began the treatment as planned, and 14 were confirmed as both eligible and having the relevant mutation. No participants were recorded as having formally "completed" the study — all 20 were listed under "not completed," which likely reflects how the trial ended or how completion was defined rather than meaning everyone dropped out. The reported data shows three main measurement...
-
NCT01679119 · results posted 17 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT01679119) enrolled 129 people in total — 65 in a group receiving a treatment combination called IO-R-CVP and 64 in a group receiving a combination called Gem-R-CVP. The trial was primarily measuring "progression-free survival," which means how long participants went without their condition getting worse or without dying. It also set out to look at a range of other things, including overall response to treatment, how long participants lived overall, side effects, quality of life, and ability to carry out everyday tasks. Th...
-
NCT04282018 · results posted 20 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04282018) enrolled a total of 96 participants across multiple groups. The trial was testing an investigational drug called BGB-10188, either on its own or combined with other medicines (zanubrutinib or tislelizumab), in people with certain blood cancers or solid tumours. The study was structured in several parts: Part A tested BGB-10188 alone at increasing doses in people with blood cancers; Part B tested it combined with zanubrutinib; Parts D and E tested it combined with tislelizumab in people with solid tumours. A key g...
-
NCT06509477 · results posted 3 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 104 people in total — 52 in each group. It was a comparison study looking at two dermal fillers (gel injections used to soften facial lines): one called Lunaphil Ultra and the other called Juvederm Ultra 4®. The main thing being measured was how much the severity of nasolabial folds — the lines that run from the sides of the nose to the corners of the mouth — changed after treatment, using a standard 1-to-5 scoring scale (where 1 means no visible fold and 5 means extreme folds). By the end of the study, 51 participant...
-
NCT03642626 · results posted 23 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 150 people across seven separate groups, each receiving a different CAR-T cell therapy (a type of treatment where a person's own immune cells are modified in a laboratory and given back to them) for a different blood cancer. The groups were: 26 people with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) receiving Kymriah (Arm A); 44 with diffuse large B-cell lymphoma (DLBCL) receiving Yescarta (Arm B); 30 with DLBCL receiving Kymriah (Arm C); 7 with mantle cell lymphoma receiving Tecartus...
-
NCT04035434 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04035434) tested an experimental treatment called CTX110 — a type of immune cell therapy — in people with two types of blood cancers: non-Hodgkin lymphoma (NHL) and B cell acute lymphoblastic leukaemia (B cell ALL). The trial ran in two stages: a dose-finding stage (Phase 1) to test different amounts of the treatment, and a larger expansion stage (Phase 2). Across all groups and dose levels, a total of 59 participants took part in the dose-finding stage and 31 in the expansion stage. The trial measured things like how many...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06018129 · results posted 23 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06018129) enrolled 9 people in total — 3 in each of three dosing groups testing a treatment called GEN3017. Participants had either classical Hodgkin lymphoma or T-cell lymphoma, two types of blood cancer. The trial was in an early dose-finding stage, meaning its main goal was to test different dose combinations (varying "priming" and "full" doses) and track certain unwanted effects, rather than to measure whether the treatment reduced cancer. No participants completed the study as defined by the trial protocol — all 9 wer...
-
NCT01996865 · results posted 10 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01996865) enrolled 503 people in an initial "induction" phase, where everyone received a combination of two medicines — lenalidomide and rituximab. Of those, 500 were actually treated, and 284 completed that phase. Participants who responded well enough were then randomly assigned to one of two maintenance (ongoing treatment) groups: 135 people continued on lenalidomide plus rituximab (Arm A), and 132 people received rituximab alone (Arm B). The trial's main goal was to measure how long people went without their condition...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00001379 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 94 people in total across four groups. The largest group — 60 people — received a treatment called interferon first, while 28 people received a combination chemotherapy-and-immunotherapy regimen (known in the trial as EPOCH-R) first. Five people were enrolled but not treated, and one person received a different combination of rituximab and radiation only. The trial was primarily measuring how many people responded to treatment (meaning their disease shrank or disappeared), and how long people went without their diseas...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03817320 · results posted 17 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03817320) looked at a drug called ixazomib given alongside chemotherapy to people with a type of blood cancer. The trial was run in two stages: the first stage tested different doses to find a safe starting point for the second stage, and the second stage looked at how many participants responded to treatment at the chosen dose. In total, 24 people were enrolled across the different groups — 3 in the first dose level of the main group (Stratum A), 20 in the second (higher) dose level of that group, and 1 person in a separa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00001337 · results posted 12 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 348 people in total — 235 received a chemotherapy combination called EPOCH-R (which includes five drugs: etoposide, doxorubicin, prednisone, cyclophosphamide, and rituximab), 112 received EPOCH without rituximab, and 1 person was enrolled but did not receive any treatment. The trial was mainly measuring how well each treatment combination reduced signs of lymphoma (a type of blood cancer), and how long participants went without their disease getting worse. The reported data shows that, for the main goal of "overall r...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02303821 · results posted 4 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02303821) enrolled 141 participants across eight groups. The trial was testing carfilzomib — a medicine given at different doses — in combination with other treatments for acute lymphoblastic leukaemia (a type of blood cancer). The study had two parts: a Phase 1b section (35 participants across six smaller groups) that tested different dose levels to examine how the drug behaved in the body, and a Phase 2 section (106 participants split into a B-cell group of 62 and a T-cell group of 44) that looked at response rates and s...
-
NCT00945724 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 54 people, all of whom received a combination treatment referred to as R-CHOP, Depocyte, and Methotrexate — three medicines used together as part of the study regimen. Of the 54 who started, 45 completed the trial and 9 did not finish. The trial was looking at how many people stopped treatment early due to unwanted side effects, and also tracking how participants fared over a five-year period in terms of their disease progressing or returning. The reported data shows that the primary thing being measured was the numb...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02953509 · results posted 29 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02953509) enrolled a total of 178 participants across ten groups. It was a two-phase study testing different doses of a drug called magrolimab, combined with rituximab (an existing cancer medicine), and in some groups also with two chemotherapy medicines (gemcitabine and oxaliplatin), in people with certain types of blood cancers called lymphomas. The earlier phase (Phase 1b) was designed to look at how often serious, treatment-related side effects called "dose-limiting toxicities" occurred — meaning unwanted reactions sev...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06138145 · results posted 18 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 125 people across four groups. The study was looking at whether different ways of asking people to sign up for a paediatric (children's health) clinical trials registry — a database of people willing to be contacted about future research studies — had any effect on their decision to enrol. The four groups were: a Control group, a Generic group, an Appeal group, and an "Ink Pen (no) Incentive" group, which appears to have involved offering a small gift (a pen) as part of the invitation approach. The reported data show...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03277729 · results posted 16 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 50 people in total across five groups, each receiving a different dose level of an experimental cell-based treatment called CD20 CAR T cells. The trial was primarily measuring whether any of the doses caused what are called "dose-limiting toxicities" — meaning serious side effects severe enough to limit how much of the treatment could be given. Participants were spread across the five dose groups, with 1, 8, 4, 6, and 31 people in each group respectively. The reported data shows that across all five dose groups, zero...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05597085 · results posted 4 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 participants, all of whom completed the study. Every participant received a treatment called Inotuzumab Ozogamicin (also referred to as InO). The trial was measuring how many participants with a type of blood cancer (acute lymphoblastic leukaemia) reached a state called "complete remission" (CR) — meaning no detectable cancer in the bone marrow and blood counts returning to normal levels — or a similar state called "complete remission with incomplete blood count recovery" (CRi), where the bone marrow also cleared b...
-
NCT03331341 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03331341) enrolled 50 participants, all of whom were placed in a single treatment group receiving a combination of four medicines known as APVD (adriamycin, pembrolizumab, vinblastine, and dacarbazine). All 50 participants who started the trial also completed it. The trial was measuring two main things: first, how many people could get through two rounds (cycles) of treatment without needing a significant delay to their dosing schedule; and second, how many people remained free of certain key events — such as their disease...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02626455 · results posted 11 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02626455) enrolled a total of 551 participants across two stages. The first stage — a safety run-in (SRI) — included 27 people who were given the drug copanlisib combined with one of two chemotherapy regimens (called R-B or R-CHOP) at different dose levels, to look at whether certain serious side effects occurred early in treatment. The second, larger stage was a randomised Phase 3 trial involving 524 people, split evenly: 262 received copanlisib combined with chemotherapy (R-B or R-CHOP), and 262 received a placebo (a dum...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02702492 · results posted 25 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02702492) tested an investigational drug called KPT-9274 in people with advanced solid tumours or blood cancers. The trial was divided into three parts: Part A tested KPT-9274 on its own at different doses (10 mg up to 40 mg); Part B tested KPT-9274 combined with a vitamin called niacin; and Part C tested KPT-9274 combined with another drug called nivolumab. In total, 60 participants started the trial across all groups and dose levels. One of the main things the trial was looking at was how the body tolerated the drug — sp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02406092 · results posted 21 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02406092) enrolled 139 people across two groups: 105 participants with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) and 34 participants with follicular lymphoma (FL). The trial was looking at a under-the-skin (subcutaneous) form of a medicine called rituximab. The main thing being measured was how many participants had a reaction linked to receiving the injection within 24 hours of each dose — this included things like injection-site reactions or other related symptoms. A number of secondary measures...
-
NCT03573700 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a cell-based treatment called SJCAR19 for children and young people aged 21 and under who had a type of blood cancer (acute lymphoblastic leukaemia, or ALL) that had come back or had not responded to earlier treatment. A total of 24 participants took part — 6 in the first dosing group and 18 in a second, higher dosing group. The trial had two aims: first, to find the highest dose that could be given without causing serious reactions (called the "maximum tolerated dose"), and second, to measure how many participants s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05315713 · results posted 4 October 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — mosunetuzumab (given as an injection under the skin) and tiragolumab (given through a drip into a vein) — in people with a type of blood cancer. The trial was designed in two phases; only the first phase (Phase 1b) appears to have produced reported results. Eight people took part in this phase, and none were recorded as having completed the study — the data shows all eight did not complete it, though the reasons for this were not detailed in the structured results. The reported data...
-
NCT04038359 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04038359) looked at a medicine called duvelisib, tested in two different dosing schedules — one group received continuous and intermittent dosing, and the other received intermittent dosing only. A total of 103 people started the trial (52 in the first group and 51 in the second), and all but one person in each group received at least one dose of the study drug. The trial was primarily measuring how many participants showed a measurable reduction in their disease, defined as either their disease disappearing completely or...
-
NCT00268853 · results posted 30 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 124 people in total — 61 in a group receiving a treatment called CPOP-R and 63 in a group receiving CHOP-R. These are two different chemotherapy-based treatment combinations. The trial was measuring how well each combination worked at reducing cancer, how long people lived, and how long it took before the disease progressed or treatment stopped working. Of the 124 who started, 45 in the CPOP-R group and 44 in the CHOP-R group completed the study. The reported data shows that, for the primary outcome of response rate,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03332017 · results posted 30 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03332017) enrolled 217 people with a type of non-Hodgkin's lymphoma — 72 in a group receiving obinutuzumab alone, and 145 in a group receiving zanubrutinib combined with obinutuzumab. The trial was primarily measuring the "overall response rate" — that is, the proportion of participants whose cancer showed a meaningful shrinkage or disappearance (called a complete or partial response) as judged by an independent review panel. The reported data shows that, based on independent central review, 45.8% of participants in the o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 167 reported results for Lymphoma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, lymphoma currently attracts a very large amount of public research funding from the United States, and that level of investment has remained broadly steady over recent years. For patients, this signals that lymphoma is a well-established research priority with a sustained scientific community working on it. Consistent funding at this level generally supports a wide r...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.